Druggability & Clinical Context
Druggability
Undruggable
Score: 0.20
Target Class
Structural Protein
Druggability Analysis
Structural Tractability0.30
Key Metrics
PDB Structures:
0
Known Drugs:
1
Approved:
0
In Clinical Trials:
0
Drug Pipeline (1 compounds)
1 Preclinical
Druggability Rationale: Based on the available data, CLDN1 presents significant challenges for neurodegeneration drug discovery due to its structural protein classification and lack of established druggable mechanisms. While preclinical anti-CLDN1 antibodies show potential and AlphaFold structural data provides some insights, the protein's tight junction modulation role makes traditional small molecule targeting difficult. The ongoing Phase 2 clinical trial evaluating safety and exploratory efficacy suggests emerging interest, but the target remains fundamentally undruggable with no clear pharmacological intervention strategy for neurological applications.
Mechanism: Tight junction protein modulation - no established druggable mechanisms
Drug Pipeline (1 compounds)
1 Preclinical
Known Drugs:Anti-CLDN1 antibodies (preclinical) — Tight junction modulator, originally for HCV entry
Structural Data:PDB —AlphaFold ✓Cryo-EM —
Selectivity & Safety Considerations
CLDN1 belongs to a 27-member claudin family with significant sequence homology, creating substantial selectivity challenges for any small-molecule modulator; antibody approaches offer superior selectivity through epitope targeting. Off-target effects on other claudins (CLDN2, CLDN3, CLDN5) could disrupt multiple tissue barriers (intestinal, renal, vascular), complicating therapeutic windows.